A retrospective cohort study using a national electronic health record database evaluates the association between a newly approved oral GLP-1 receptor agonist and the incidence of acute pancreatitis in patients with type 2 diabetes. The comparator group consists of patients prescribed DPP-4 inhibitors. Initial analysis yields a crude relative risk of 1.8 (95% CI: 1.4 - 2.3) for acute pancreatitis in the GLP-1 agonist group.
Upon further review, the investigators note that the GLP-1 agonist was disproportionately prescribed to patients with a higher baseline body mass index (BMI), a longer duration of diabetes, and a prior history of hypertriglyceridemia. All of these factors are known independent risk factors for acute pancreatitis. The researchers recognize that this unequal distribution of baseline characteristics constitutes confounding by indication and threatens the internal validity of the study.
Which of the following strategies represent valid methods to control for this specific methodological threat during the analysis phase of this study? (Select all that apply)
- Multivariable regression analysis incorporating BMI, diabetes duration, and hypertriglyceridemia as covariatesAnswer
- Propensity score matching of patients in the GLP-1 agonist and DPP-4 inhibitor groups based on baseline characteristicsAnswer
- CReporting stratum-specific relative risks for demographic variables to determine if the drug's risk profile differs across subgroups
- DRetroactively applying blocked randomization to the existing electronic health record data to distribute covariates evenly
- ECalculating the positive and negative predictive values of the GLP-1 agonist for predicting acute pancreatitis